Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Zundler

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 22, 2025
Accuracy of superb microvascular imaging (SMI) in predicting endoscopic Crohn's disease activitySophie Haberkamp, David Fischmann, Judith Wilde, et al.
Inflammatory Bowel Diseases|March 8, 2025
Superb Microvascular Imaging Is Superior to Doppler Imaging in Ruling Out Ulcerative Colitis Disease ActivitySophie Haberkamp, David Fischmann, Judith Wilde, et al.
Gut|July 26, 2015
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivoAnika Fischer, Sebastian Zundler, Raja Atreya, et al.
Inflammatory Bowel Diseases|February 22, 2017
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In VivoSebastian Zundler, Anika Fischer, Daniela Schillinger, et al.
Therapeutic Advances in Gastroenterology|December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitisMichaela Melde, Tanja M Müller, Ines Schneider, et al.
BMC Gastroenterology|April 16, 2020
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort studyClarissa Allner, Michaela Melde, Emily Becker, et al.
BMJ Open|December 9, 2021
Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trialCaroline J Voskens, Diane Stoica, Susanne Roessner, et al.
Therapeutic Advances in Gastroenterology|January 28, 2021
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximabSarah Fischer, Sarah Cohnen, Entcho Klenske, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|October 22, 2022
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel diseaseInes Schneider, Clarissa Allner, Laura Mühl, et al.
Clinical and Translational Medicine|April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healingKatrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 22, 2025
Accuracy of superb microvascular imaging (SMI) in predicting endoscopic Crohn's disease activitySophie Haberkamp, David Fischmann, Judith Wilde, et al.
Inflammatory Bowel Diseases|March 8, 2025
Superb Microvascular Imaging Is Superior to Doppler Imaging in Ruling Out Ulcerative Colitis Disease ActivitySophie Haberkamp, David Fischmann, Judith Wilde, et al.
Gut|July 26, 2015
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivoAnika Fischer, Sebastian Zundler, Raja Atreya, et al.
Inflammatory Bowel Diseases|February 22, 2017
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In VivoSebastian Zundler, Anika Fischer, Daniela Schillinger, et al.
Therapeutic Advances in Gastroenterology|December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitisMichaela Melde, Tanja M Müller, Ines Schneider, et al.
BMC Gastroenterology|April 16, 2020
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort studyClarissa Allner, Michaela Melde, Emily Becker, et al.
BMJ Open|December 9, 2021
Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trialCaroline J Voskens, Diane Stoica, Susanne Roessner, et al.
Therapeutic Advances in Gastroenterology|January 28, 2021
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximabSarah Fischer, Sarah Cohnen, Entcho Klenske, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|October 22, 2022
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel diseaseInes Schneider, Clarissa Allner, Laura Mühl, et al.
Clinical and Translational Medicine|April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healingKatrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Pageof 10